Suputtamongkol Y et al., 2021-05-18: Two consecutive randomized placebo-controlled dengue trials in Thailand (203 patients in the combined intention-to-treat analysis) showing faster NS1 antigen clearance with three days of ivermectin but no effect on viremia or clinical outcomes.
A 3-day 1 daily dose of 400 µg/kg oral ivermectin was safe and accelerated NS1 antigenemia clearance in dengue patients. However, clinical efficacy of ivermectin was not observed at this dosage regimen.
Suputtamongkol Y et al., 2021-05-18: Two consecutive randomized placebo-controlled dengue trials in Thailand (203 patients in the combined intention-to-treat analysis) showing faster NS1 antigen clearance with three days of ivermectin but no effect on viremia or clinical outcomes. Combined phase 2 and phase 3 randomized, double-blind, placebo-controlled trials, Thailand; 203 patients in the ITT analysis (100 ivermectin, 103 placebo); ivermectin 400 micrograms/kg once daily for 3 days in phase 3. At discharge 72.0% vs 47.6% had undetectable plasma NS1 (P=.001); no difference in viremia clearance time or adverse events; no clinical efficacy at this regimen. Funder and conflicts not carried in the PubMed record. Bearing PARTLY SUPPORTS: the virological endpoint moved, the clinical one did not. Correction to the prompt lead: the paper is indexed under Suputtamongkol Y as first author with Yamasmith E among the co-authors, not 'Yamasmith E et al.'; same trial. Study type: randomized trial.
